COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04480840
Recruitment Status : Recruiting
First Posted : July 21, 2020
Last Update Posted : December 21, 2020
Information provided by (Responsible Party):
Pliant Therapeutics, Inc.

Brief Summary:
A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis

Condition or disease Intervention/treatment Phase
Primary Sclerosing Cholangitis Drug: PLN-74809 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)
Actual Study Start Date : July 27, 2020
Estimated Primary Completion Date : February 28, 2022
Estimated Study Completion Date : March 30, 2022

Arm Intervention/treatment
Placebo Comparator: Placebo Drug: Placebo

Experimental: PLN-74809 Dose Level 1 Drug: PLN-74809

Experimental: PLN-74809 Dose Level 2
PLN-74809 Dose Level 2 following safety review of PLN-74809 Dose Level 1
Drug: PLN-74809

Experimental: PLN-74809 Dose Level 3
PLN-74809 Dose Level 3 following safety review of PLN-74809 Dose Level 1
Drug: PLN-74809

Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events and laboratory abnormalities, as assessed by CTCAE v5.0 [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Assessment of PLN-74809 plasma concentrations [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Established clinical diagnosis of large duct PSC based on an abnormal cholangiography as assessed by magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), and/or percutaneous transhepatic cholangiopancreatography (PTC) in the context of cholestatic liver chemistry
  • Suspected liver fibrosis, as defined by liver stiffness measurement (LSM), assessed by ultrasound-based transient elastography (TE, FibroScan®)
  • Serum ALP concentration > 1.5 times the upper limit of normal (ULN)
  • Participants receiving treatment for IBD are allowed, if on a stable dose for at least 3 months
  • Serum AST and ALT concentration ≤ 5 times the upper limit of normal
  • If receiving treatment with UDCA, therapy is at a dose of < 25 mg/kg/day, has been stable for at least 3 months before screening.

Exclusion Criteria:

  • Other causes of liver disease, including secondary sclerosing cholangitis or viral, metabolic, or alcoholic liver disease, as assessed clinically
  • Known or suspected overlapping clinical and histologic diagnosis of autoimmune hepatitis
  • Small duct PSC (evidence of PSC on historical liver histology, with normal bile ducts on cholangiography)
  • Presence of liver cirrhosis as assessed by historical liver histology, ultrasound-based liver stiffness measurement (FibroScan® value > 14.4 kPa), and/or signs and symptoms of hepatic decompensation (including, but not limited to, jaundice, ascites, variceal hemorrhage, and/or hepatic encephalopathy)
  • Serum ALP concentration > 10 times the upper limit of normal.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04480840

Layout table for location contacts
Contact: Pliant Therapeutics Medical Monitor

Show Show 22 study locations
Sponsors and Collaborators
Pliant Therapeutics, Inc.
Layout table for investigator information
Study Director: Pliant Therapeutics Medical Monitor Pliant Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Pliant Therapeutics, Inc. Identifier: NCT04480840    
Other Study ID Numbers: PLN-74809-PSC-203
INTEGRIS-PSC ( Other Identifier: Pliant Therapeutics] )
First Posted: July 21, 2020    Key Record Dates
Last Update Posted: December 21, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholangitis, Sclerosing
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases